Avita Medical, a regenerative medicine company pitching a spray-on skin to burn patients, says it will miss its revenue forecasts, sending shares sliding by a fifth to just a third of its record $1.2 billion valuation.
Treatment of patchy pigmentation from autoimmune disease vitiligo is a key market for Avita. Bella Management
